CD276 and neuroblastoma: In view of the results herein obtained, the simultaneous combination targeting of GD2, B7-H3 and NCL, by means of Dinutuximab [39], chimeric antigen receptor (CAR) T cells targeting B7-H3 (B7-H3.CAR-Ts) [40] and PEGASEMPTM, might represent an innovative and useful strategy for refractory/relapsed NB patients.